$125.00
12mg Total Triple Blend (6mg Tesamorelin / 3mg CJC-1295 No DAC / 3mg Ipamorelin) – Lyophilized *MUST BE RECONSTITUTED FOR RESEARCH APPLICATIONS*
This advanced, high-purity triple-blend formulation pairs Tesamorelin (6mg), CJC-1295 No DAC (3mg), and Ipamorelin (3mg) to explore maximum multi-pathway growth hormone amplification and tissue-level remodeling synergy. By combining dual structural GHRH receptor agonists with a highly selective ghrelin mimetic to fire pituitary somatotrophs while simultaneously blocking somatostatin inhibition, this stable 12mg presentation stands as a premier investigative tool for tracking advanced visceral adipose tissue (VAT) reduction, accelerated hepatic IGF-1 transcription, and lean skeletal muscle preservation in laboratory models.
Supplied as a stable, premium-grade lyophilized powder blend in a single 12mg vial. Restricted strictly to laboratory and in vitro evaluation.
Eterna Peptides presents premium-grade Tesamorelin, CJC-1295 No DAC, and Ipamorelin blend, an advanced triple-action growth hormone secretagogue (GHS) research formulation. Combining three distinct, highly purified synthetic peptide chains—Tesamorelin (6mg), CJC-1295 No DAC (3mg), and Ipamorelin (3mg)—in a single precisely calibrated 12mg vial, this synergistic matrix serves as an elite investigative tool for tracking multi-pathway somatotroph stimulation, accelerated visceral adiposity mobilization, and targeted musculoskeletal recovery kinetics.
### Advanced 12mg Synergistic Peptide Profile
Each carefully calibrated vial delivers a precise, uniform mass distribution of targeted secretagogue compounds:
* **Tesamorelin (6mg):** A synthetic 44-amino-acid peptide analogue of endogenous Growth Hormone-Releasing Hormone (GHRH). Featuring a stabilized hexenoyl group addition that resists enzymatic degradation, it is intensively researched for its profound lipolysis pathways, visceral adipose tissue (VAT) reduction, and hepatic insulin-like growth factor-1 (IGF-1) transcription regulation.
* **CJC-1295 No DAC (3mg):** A synthetic 30-amino-acid tetrasubstituted peptide analogue of GHRH. Characterized by the exclusion of the Drug Affinity Complex (DAC) for a cleaner, high-amplitude acute signaling arc, it modifies specific amino acid positions to resist dipeptidyl ppetidase-4 (DPP-4) enzymatic cleavage, driving extended GHRH receptor affinity.
* **Ipamorelin (3mg):** A highly selective synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) ghrelin receptor agonist. It functions as a targeted somatotroph stimulant, triggering growth hormone secretion waves without shifting baseline physiological cortisol, prolactin, or aldosterone profiles.
### Mechanism of Action
The Tesamorelin / CJC-1295 / Ipamorelin triple matrix simultaneously targets three distinct neuroendocrine receptor pathways to maximize natural, pulsatile growth hormone output:
* **Amplified Pituitary GHRH Pathway Saturation:** Tesamorelin and CJC-1295 No DAC work in tandem to saturate peripheral GHRH receptors on pituitary somatotroph cells. This dual-GHRH approach triggers a massive upregulation in the synthesis and baseline storage of endogenous Growth Hormone ($GH$).
* **Concurrent Somatostatin Suppression:** Simultaneously, Ipamorelin selectively activates the Growth Hormone Secretagogue Receptor (GHS-R), mimicking ghrelin to actively suppress somatostatin (growth hormone-inhibiting hormone). By removing this inhibitory ceiling while concurrently firing the GHRH engines, the triple blend coaxes out the highest possible physiological amplitude of natural growth hormone pulses.
* **Visceral Fat Oxidation & Repartitioning:** The resulting downstream somatotropic wave drives continuous lipolysis, specifically tracking the breakdown of deep visceral adipose tissue and studying systemic lipid profile improvements under metabolic stress modeling.
* **Downstream IGF-1 Transcription & Repair:** Increased circulating GH signals the liver to accelerate the expression of Insulin-like Growth Factor-1 ($IGF\text{-}1$), which is monitored for its primary roles in cellular protein synthesis, lean myofibrillar preservation, satellite cell activation, and soft tissue wound healing.
### Research Applications
In preclinical and in vitro laboratory models, this triple-GHS blend is actively utilized to investigate:
* High-velocity visceral fat mobilization, lipid beta-oxidation kinetics, and advanced metabolic rate repartitioning.
* Musculoskeletal structural remodeling, myofibrillar preservation, and connective tissue recovery curves.
* Comprehensive pathway saturation profiles where dual-acting GHRH analogues and selective ghrelin mimetics intersect.
* Slow-wave sleep architecture optimization, delta-wave sleep tracking, and age-related cognitive/hormonal longevity indicators.
Our triple blend vials undergo strict laboratory stabilization, high-grade purification, and uniform vacuum-drying guidelines to ensure an exact 6mg:3mg:3mg mass ratio, absolute structural purity, and dependable experimental reproducibility.
—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*
